Market Research Industry Reports

Colorectal Cancer - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Colorectal Cancer - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2017, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason. Risk factors include smoking, heavy alcohol use, inflammatory bowel disease (IBD) and family history. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 26, 110, 143, 11, 175, 29 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 20, 9, 33 and 4 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
Introduction 11
Colorectal Cancer - Overview 12
Colorectal Cancer - Therapeutics Development 13
Colorectal Cancer - Therapeutics Assessment 70
Colorectal Cancer - Companies Involved in Therapeutics Development 100
Colorectal Cancer - Drug Profiles 211
Colorectal Cancer - Dormant Projects 1872
Colorectal Cancer - Discontinued Products 1891
Colorectal Cancer - Product Development Milestones 1896
Appendix 1906

List Of Tables


Number of Products under Development for Colorectal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Colorectal Cancer - Pipeline by 3-V Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by 3SBio Inc, H2 2017
Colorectal Cancer - Pipeline by 4SC AG, H2 2017
Colorectal Cancer - Pipeline by AB Science SA, H2 2017
Colorectal Cancer - Pipeline by AbbVie Inc, H2 2017
Colorectal Cancer - Pipeline by AbGenomics International Inc, H2 2017
Colorectal Cancer - Pipeline by Aclaris Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by Adamed Sp z oo, H2 2017
Colorectal Cancer - Pipeline by Aduro BioTech Inc, H2 2017
Colorectal Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Colorectal Cancer - Pipeline by AlfaSigma SpA, H2 2017
Colorectal Cancer - Pipeline by Allinky Biopharma, H2 2017
Colorectal Cancer - Pipeline by amcure GmbH, H2 2017
Colorectal Cancer - Pipeline by Amgen Inc, H2 2017
Colorectal Cancer - Pipeline by Amunix Operating Inc, H2 2017
Colorectal Cancer - Pipeline by Antibe Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by APEIRON Biologics AG, H2 2017
Colorectal Cancer - Pipeline by Apexigen Inc, H2 2017
Colorectal Cancer - Pipeline by Aphios Corp, H2 2017
Colorectal Cancer - Pipeline by Aposense Ltd, H2 2017
Colorectal Cancer - Pipeline by Arisaph Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by ARMO Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by ArQule Inc, H2 2017
Colorectal Cancer - Pipeline by Array BioPharma Inc, H2 2017
Colorectal Cancer - Pipeline by Asana BioSciences LLC, H2 2017
Colorectal Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2017
Colorectal Cancer - Pipeline by Astellas Pharma Inc, H2 2017
Colorectal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by AstraZeneca Plc, H2 2017
Colorectal Cancer - Pipeline by Aurobindo Pharma Ltd, H2 2017
Colorectal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by B Cell Design SAS, H2 2017
Colorectal Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2017
Colorectal Cancer - Pipeline by Bavarian Nordic A/S, H2 2017
Colorectal Cancer - Pipeline by Bayer AG, H2 2017
Colorectal Cancer - Pipeline by BeiGene Ltd, H2 2017
Colorectal Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2017
Colorectal Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by Biocon Ltd, H2 2017
Colorectal Cancer - Pipeline by Bionomics Ltd, H2 2017
Colorectal Cancer - Pipeline by Bionovis SA, H2 2017
Colorectal Cancer - Pipeline by Biotecnol Ltd, H2 2017
Colorectal Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2017
Colorectal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Colorectal Cancer - Pipeline by Boston Biomedical Inc, H2 2017
Colorectal Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2017
Colorectal Cancer - Pipeline by Calithera Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by Cantargia AB, H2 2017
Colorectal Cancer - Pipeline by Carna Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Cascadian Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2017
Colorectal Cancer - Pipeline by CCRP Therapeutics GmbH, H2 2017
Colorectal Cancer - Pipeline by Celgene Corp, H2 2017
Colorectal Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Colorectal Cancer - Pipeline by Cellectar Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Celleron Therapeutics Ltd, H2 2017
Colorectal Cancer - Pipeline by Celltrion Inc, H2 2017
Colorectal Cancer - Pipeline by Celyad SA, H2 2017
Colorectal Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2017
Colorectal Cancer - Pipeline by ChoDang Pharm Co Ltd, H2 2017
Colorectal Cancer - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Colorectal Cancer - Pipeline by Cleave Biosciences Inc, H2 2017
Colorectal Cancer - Pipeline by Cleveland BioLabs Inc, H2 2017
Colorectal Cancer - Pipeline by COARE Biotechnology Inc, H2 2017

List Of Figures


Number of Products under Development for Colorectal Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Colorectal Cancer: Competitive Landscape to 2026

Colorectal Cancer: Competitive Landscape to 2026Colorectal cancer (CRC) is a cancer that originates in either the colon or the rectum. CRC is the fourth leading cause of mortality among cancer

USD 3495View Report

Global Colorectal Cancer Drug Market Research Report 2018

Colorectal Cancer Drug Report by Material, Application, and Geography Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on

USD 2850View Report

Bladder Cancer - Pipeline Review, H1 2018

Bladder Cancer - Pipeline Review, H1 2018Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H1 2018, provides an overview of the Bladder Cancer

USD 2500View Report

Colorectal Cancer: Competitive Landscape to 2026

Colorectal Cancer: Competitive Landscape to 2026Colorectal cancer (CRC) is a cancer that originates in either the colon or the rectum. CRC is the fourth leading cause of mortality among cancer

USD 3495View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2500
  • Site Licence    USD 5000
  • Enterprise Wide Licence    USD 7500
$ 2500

Reports Details

Published Date : Dec 2017
No. of Pages :1962
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube